** Shares of Lexicon Pharmaceuticals LXRX.O drop 11.75% to 63 cents before the bell
** Late on Friday, U.S. FDA declined to approve the biopharma company's add-on drug for type 1 diabetes and chronic kidney disease
** Company had previously disclosed its strategic decision to discontinue launch preparations for the drug
** Company had said in November it would reduce its workforce by about 60%, after the U.S. FDA noted deficiencies in its application seeking approval for its diabetes drug
** LXRX to focus on development of other products
** A panel of advisers to the FDA had voted against recommending the drug, sotagliflozin, as an add-on treatment to insulin therapy for managing blood glucose levels in adults with type 1 diabetes and chronic kidney disease
** Up to last close, stock down ~53% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。